TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7527108

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Nifedipine slow-release (SR) 20 mg twice daily
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Combination of trandolapril and nifedipine SR
Number of subjects: 161

Group type: COMPARATOR
Intervention: Nifedipine SR
Number of subjects: 161
Study: 2662743

Group type: EXPERIMENTAL
Intervention: Atenolol, 50 to 200 mg once daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 to 30 mg 3 times daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 39
Study: 30418099

Group type: EXPERIMENTAL
Intervention: Single-Incision and One-Puncture Laparoscopic Appendectomy (SIOPLA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional Three-Port Laparoscopic Appendectomy (CLA)
Number of subjects: 72
Study: 28111980

Group type: EXPERIMENTAL
Intervention: Exercise for 12 months
Number of subjects: 137
Study: 26412801

Group type: EXPERIMENTAL
Intervention: Higher-bioavailability BNX sublingual tablet
Number of subjects: 758

Group type: COMPARATOR
Intervention: Generic buprenorphine
Number of subjects: 758

Group type: COMPARATOR
Intervention: BNX film
Number of subjects: 758
Study: 23797603

Group type: EXPERIMENTAL
Intervention: Pegaptanib DHPC + MEB e-mail (Intervention group, N = 110)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Traditional paper-based DHPC only (Control group, N = 105)
Number of subjects: 215
Study: 21453657

Group type: EXPERIMENTAL
Intervention: Tissue pre-expansion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (unexpanded radial forearm free flap donor site skin)
Number of subjects: 29
Study: 19556972

Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aliskiren combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy or combination therapy
Number of subjects: 0
Study: 16681573

Group type: EXPERIMENTAL
Intervention: Bath PUVA (n = 9)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MD-UVA1 (n = 11)
Number of subjects: 33

Group type: COMPARATOR
Intervention: NB-UVB (n = 13)
Number of subjects: 33
Study: 15517078

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily for 4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (5 women, same age range as PCOS women)
Number of subjects: 19

Group type: COMPARATOR
Intervention: PCOS women (untreated)
Number of subjects: 19
Study: 11781669

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (200,000 IU) on admission and placebo daily until discharge
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin A (5,000 IU) daily from admission until discharge
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo daily from admission until discharge
Number of subjects: 900
Study: 9264493

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg BID)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 8496306

Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham tryptophan depletion
Number of subjects: 8
Study: 31503155

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg daily
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 28850380

Group type: EXPERIMENTAL
Intervention: Combat system (computerized clinical decision support tool)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Paper-and-pencil method (control group)
Number of subjects: 214
Study: 25346093

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate topical gel (once daily for 8 weeks)
Number of subjects: 1795
Study: 23001413

Group type: EXPERIMENTAL
Intervention: 2-butanol (40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breath test for adherence monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-butanol ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tongue application of 2-butanol
Number of subjects: 0
Study: 21972410

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control with gliclazide modified release targeting HbA1c of ≤6.5%
Number of subjects: 11140
Study: 19345789

Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses made from EVA for 8 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Customized foot orthoses made from EVA for 8 weeks
Number of subjects: 142
Study: 16461832

Group type: EXPERIMENTAL
Intervention: Prior LA ablation patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 15253730

Group type: EXPERIMENTAL
Intervention: Early treatment with erythropoietin alpha (50 U/kg/wk)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Deferred treatment (erythropoietin initiated when hemoglobin <9 g/dL)
Number of subjects: 88
Study: 11817199

Group type: EXPERIMENTAL
Intervention: Healthwise Communities Project (HCP) - includes distribution of the Healthwise Handbook, telephone advice line, and website.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control communities (comparison communities)
Number of subjects: 0
Study: 9385487

Group type: EXPERIMENTAL
Intervention: Once-daily (QD) formulation of loratadine 10 mg and pseudoephedrine sulfate 240 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Twice-daily (BID) formulation of loratadine 5 mg and pseudoephedrine sulfate 120 mg
Number of subjects: 24
Study: 8100153

Group type: EXPERIMENTAL
Intervention: UDCA 600 mg/day for 3 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Long-term UDCA treatment (mean 20 months)
Number of subjects: 19
Study: 3548493

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (200 mg intravenous)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiological saline solution (placebo)
Number of subjects: 10
Study: 29538579

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 60
Study: 27496232

Group type: EXPERIMENTAL
Intervention: calcifediol 0.266 mg capsules for 15 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: calcifediol
Number of subjects: 144
Study: 24241495

Group type: EXPERIMENTAL
Intervention: Iron loading (1.25 mg/kg iron sucrose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Iron chelation therapy (30 mg/kg deferasirox)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Labile plasma iron
Number of subjects: 30
Study: 21300466

Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin and hyperfractionated radiotherapy (cisplatin 20 mg/m² for 5 consecutive days during weeks 1 and 5, median total dose 74.4 Gy; 1.2 Gy twice daily; 5 days per week)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy alone (median total dose, 74.4 Gy; 1.2 Gy twice daily; 5 days per week)
Number of subjects: 224
Study: 20147896

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) 500 mg/200 mg b.i.d.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Multiple dosing of TPV/r
Number of subjects: 23
Study: 17907263

Group type: EXPERIMENTAL
Intervention: 1.75 mg ST zolpidem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3.5 mg ST zolpidem
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 mg ST zolpidem
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16756690

Group type: EXPERIMENTAL
Intervention: Bright light (10,000 lux)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Auditory stimuli (60 dB)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: High-density negative ions (4.5x10(14) ions/s)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low-density negative ions (1.7x10(11) ions/s; placebo control)
Number of subjects: 118
Study: 14663041

Group type: EXPERIMENTAL
Intervention: riluzole 200 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: riluzole 100 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 11054627

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8864970

Group type: EXPERIMENTAL
Intervention: Conservative treatment mainly using spinal manipulation
Number of subjects: 59
Study: 1378155

Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg once daily, starting at 12.5 mg for 2 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Atenolol (50-100 mg once daily, starting at 50 mg)
Number of subjects: 99
Study: 6700642

Group type: EXPERIMENTAL
Intervention: Tonsillectomy or tonsillectomy with adenoidectomy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 187
Study: 31661015

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation screening trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29093302

Group type: EXPERIMENTAL
Intervention: Self-monitoring device for urinary sodium-to-potassium ratio
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 92
Study: 26993372

Group type: EXPERIMENTAL
Intervention: Moderate ibudilast (40 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-dose ibudilast (100 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 25233662

Group type: EXPERIMENTAL
Intervention: Frequency acupoint electrical stimulation at Ciliao (BL 32) and Shenshu (BL 23), disperse‐densewave, 2 Hz/100 Hz for 15 to 20 min.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous anesthesia of propofol.
Number of subjects: 90
Study: 21893345

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) insertion
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intubation with the Macintosh blade
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intubation with a videolaryngoscope (GlideScope)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Severity of dental trauma
Number of subjects: 96
Study: 23163191

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7vPCV) administered at ages 0, 1, and 2 months or at 1, 2, and 3 months
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Community engagement and strong research partnership
Number of subjects: 318
Study: 17343999

Group type: EXPERIMENTAL
Intervention: Dissolution test using paddle, 900ml of medium containing water with 0.7% (w/v) sodium lauryl sulfate at a rotation speed of 25rpm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPLC method for dissolution test
Number of subjects: 0
Study: 16617617

Group type: EXPERIMENTAL
Intervention: Virtual reality visual stimulation combined with force platform posturography
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Series of tests with different visual and mechanical stimuli
Number of subjects: 110
Study: 14651352

Group type: EXPERIMENTAL
Intervention: BMIPP uptake in DCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BMIPP washout in DCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BMIPP uptake in HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BMIPP washout in HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Global BMIPP parameters correlation with LVEF in DCM and HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Global BMIPP parameters correlation with H/M-TF in DCM and HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early H/M as a predictor for H/M-TF in DCM and HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regional BMIPP parameters correlation with regional function in DCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regional BMIPP parameters correlation with regional perfusion in DCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regional BMIPP parameters correlation with regional function in HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regional BMIPP parameters correlation with regional perfusion in HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Delayed regional BMIPP uptake in HCM
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early regional BMIPP uptake in DCM and HCM
Number of subjects: 39
Study: 10480773

Group type: EXPERIMENTAL
Intervention: Erlangen micro lightguide spectrophotometer (EMPHO II) measuring SaO2
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control sites (not specified)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ulcers that did not heal
Number of subjects: 14
Study: 8857017

Group type: EXPERIMENTAL
Intervention: Cardiac troponin I levels of at least 0.4 ng/mL
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Cardiac troponin I levels below 0.4 ng/mL
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Increase of 1 ng/mL in cardiac troponin I level
Number of subjects: 1404
Study: 1764383

Group type: EXPERIMENTAL
Intervention: Early stage protocol (adjuvant therapy)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Advanced stages protocol (chemotherapy treatment)
Number of subjects: 481
Study: 6846738

Group type: EXPERIMENTAL
Intervention: Budesonide treatment for 1 week
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment for 1 week
Number of subjects: 14
Study: 31487573

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) delivered as therapist-guided bibliotherapy
Number of subjects: 61
Study: 28887626

Group type: EXPERIMENTAL
Intervention: Punishment in 100% of adaptation trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reward in 100% of adaptation trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Punishment in 50% of adaptation trials (randomly selected)
Number of subjects: 0
Study: 25377567

Group type: EXPERIMENTAL
Intervention: Mefloquine in combination with artesunate
Number of subjects: 67
Study: 24342543

Group type: EXPERIMENTAL
Intervention: Continuous heart rate and respiration rate monitoring in the intervention unit postimplementation.
Number of subjects: 7643

Group type: COMPARATOR
Intervention: Control unit (no continuous monitoring).
Number of subjects: 7643
Study: 21982325

Group type: EXPERIMENTAL
Intervention: Water-based exercise program (12 weeks, twice weekly)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Time-matched computer training program (control group)
Number of subjects: 39
Study: 19233760

Group type: EXPERIMENTAL
Intervention: Double-clamp technique (DCT)
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Single-clamp technique (SCT)
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Off-pump technique
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: On-pump cross-clamp off technique
Number of subjects: 890

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 890
Study: 17725246

Group type: EXPERIMENTAL
Intervention: Moxonidine, 0.6 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Atenolol, 50 mg/day
Number of subjects: 98
Study: 15077101

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 3140
Study: 11717602

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9153445

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (mean dose 381 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7895790

Group type: EXPERIMENTAL
Intervention: Optokinetic (OK) stimulation rehabilitation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic posturography (Equitest) measurements
Number of subjects: 0
Study: 2949197

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo control (nonaerobic recreational games or no exercise)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Beta-endorphin levels
Number of subjects: 430
Study: 30683124

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) with a self‐stretching home program
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Percutaneous Needle Electrolysis (PNE) with a self‐stretching home program
Number of subjects: 94
Study: 30115258

Group type: EXPERIMENTAL
Intervention: Propofol-based general anaesthesia
Number of subjects: 392

Group type: COMPARATOR
Intervention: Sevoflurane-based general anaesthesia
Number of subjects: 392
Study: 27039035

Group type: EXPERIMENTAL
Intervention: ayahuasca (0.75mg DMT/kg body weight)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ketanserin (40mg) + ayahuasca (0.75mg DMT/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo + ayahuasca (0.75mg DMT/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: ketanserin (40mg) + placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 12
Study: 24612502

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day) plus letrozole (2.5 mg/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo plus letrozole (2.5 mg/day)
Number of subjects: 104
Study: 23808868

Group type: EXPERIMENTAL
Intervention: Cocaine use (<30 days abstinence)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Methamphetamine use
Number of subjects: 165
Study: 21072738

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (WBVT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 19009170

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CO)
Number of subjects: 22
Study: 16303837

Group type: EXPERIMENTAL
Intervention: recombinant hGH treatment (0.1 or 0.2 IU/kg.d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15094704

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 27
Study: 11095060

Group type: EXPERIMENTAL
Intervention: Patients with ACD
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with LCD type 1 (LCD1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with atypical LCDI
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with LCD with opacities deep in stroma
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with GCD
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with RBCD
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 117
Study: 8931531

Group type: EXPERIMENTAL
Intervention: Strength training (3 to 4 sets of 8 to 10 repetitions with a load of 60% to 75% of the subjects' 1‐repetition maximum)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Endurance training (track walking and step aerobics at an intensity of 50% to 80% of maximum heart‐rate reserve)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 1349491

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmeterol 200 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmeterol 400 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6269418

Group type: EXPERIMENTAL
Intervention: High fiber diet (fruits and vegetables)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low fiber diet (fruit and vegetable juices)
Number of subjects: 12
Study: 30689513

Group type: EXPERIMENTAL
Intervention: MOTR+GPM‐BV
Number of subjects: 60

Group type: COMPARATOR
Intervention: GPM‐BV
Number of subjects: 60
Study: 30894146

Group type: EXPERIMENTAL
Intervention: Medial unicondylar knee arthroplasty (mUKA)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 350
Study: 29092886

Group type: EXPERIMENTAL
Intervention: 2RDA (1.6 g protein · kg‐1 · d‐1)
Number of subjects: 29

Group type: COMPARATOR
Intervention: RDA (0.8 g protein · kg‐1 · d‐1)
Number of subjects: 29
Study: 25775249

Group type: EXPERIMENTAL
Intervention: Prolonged sedentary time (30 min/day less) and light-intensity activity (30 min/day more)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Prolonged sedentary time (30 min/day less) and non-prolonged sedentary time (30 min/day more)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Prolonged sedentary time (30 min/day less) and light-intensity time (30 min/day more)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Light-intensity activity
Number of subjects: 279
Study: 23806736

Group type: EXPERIMENTAL
Intervention: α-cyclodextrin (2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21729265

Group type: EXPERIMENTAL
Intervention: Case management program in addition to diabetes management program
Number of subjects: 230

Group type: COMPARATOR
Intervention: Care-as-usual from general practitioner and other care providers
Number of subjects: 230
Study: 19297572

Group type: EXPERIMENTAL
Intervention: CMV vaccine (recombinant CMV envelope glycoprotein B with MF59 adjuvant)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: CMV vaccine
Number of subjects: 464
Study: 18085104

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil‐based anesthesia and analgesia (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined general‐epidural anesthesia (group C)
Number of subjects: 60
Study: 17144474

Group type: EXPERIMENTAL
Intervention: Xiaozheng pills
Number of subjects: 240

Group type: COMPARATOR
Intervention: Rujiekang mimetic (placebo)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups (trial and control)
Number of subjects: 240
Study: 12886586

Group type: EXPERIMENTAL
Intervention: Combined use of essentiale and T‐activin
Number of subjects: 117